Marina Biotech and Girindus Group have entered into a strategic alliance under which Girindus will have exclusive rights to develop, supply and commercialize certain oligonucleotide constructs using Marina’s Conformationally Restricted Nucleotide (CRN) chemistry. Marina will receive royalties from the sale of CRN-based oligonucleotide reagents as well as supply of cGMP material for Marina and its partners’ preclinical, clinical and commercialization needs.   Marc Lemaitre, chief exec...